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encouraged to consider this tool in constructing future economic
models.
PMD5
TRACING THE DIFFUSION OF COST-UTILITY ANALYSIS AS
AN INNOVATION
Sonnad SS1, Greenberg D2, Rosen AB2, Olchanski NV2, Chapman R2,
Neumann PJ2
1University of Pennsylvania, Philadelphia, PA, USA; 2Harvard School of
Public Health, Boston, MA, USA
OBJECTIVE: Cost utility analysis (CUA) ﬁrst entered the 
literature in the 1970s and is now considered the standard for
examining the cost-effectiveness of health related interventions.
This study considers CUA as a methodological innovation and
traces its diffusion through the medically related literature for
twenty-ﬁve years. METHODS: We used the bibliography 
compiled at the Harvard School of Public Health
(http://www.hsph.harvard.edu/cearegistry/). All articles are orig-
inal CUAs indexed in MEDLINE and other electronic databases
from 1976 to 2001. For each article, we identiﬁed clinical area,
journal title and type (methods, general medicine, medical spe-
cialty, and other specialty). Medical specialty refers to those ﬁelds
considered subspecialties of medicine, such as cardiology and
gastroenterology, while other specialties include ﬁelds such as
radiology, surgery, nursing and pharmacology. We examined dis-
semination patterns of CUAs, and whether we could trace their
spread through the literature over time. RESULTS: The number
of CUAs (n = 539) plotted against year of publication yielded an
S-shaped curve, matching the classic diffusion pattern seen for
other innovations. Moreover, CUAs have diffused over time from
general medical journals and methodological journals into a
wide variety of specialty journals, tracing the typical pattern of
dissemination and adoption seen for other innovations. In
summary, for journal types methods, general medicine, medical
specialty, and other specialty, respectively, distribution of pub-
lished CUAs changed from 29%, 57%, 14%, and 0% during
1976–1984 to 14%, 29%, 37%, and 20% during 1998–2001
with transitional values in intervening time periods. CONCLU-
SIONS: The spread of CUAs through the literature follows pat-
terns commonly seen in the diffusion of innovations. It is
important to note that diffusion does not equal implementation.
Further study is required to determine whether the diffusion of
CUA has been accompanied by increasing use for decision
making in clinical practice or health policy.
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OBJECTIVES: Health care costs are rarely directly observed for
clinical trial subjects. What can be observed is medical resource
use. Designing a resource costing strategy involves determining
the degree of detailed resource data to collect and identifying unit
prices for those speciﬁc resources. A higher level of detail can
create a more speciﬁc estimate of costs, but this strategy increases
investigator burden. Our objective is to lay out the conceptual
framework of resource costing, draw implications, and provide
recommendations for weighing the tradeoffs of the design deci-
sions of resource costing. METHODS: For simplicity, assume
that medical costs are composed of two types of resources, X
and Y. Unit prices for resources X and Y are denoted px and py.
Now consider a bundled resource unit, Z where Z = X + Y. The
unit price for Z is pz = px + w*py where w = proportion of X in
price population. From this notation, we determine differences
in incremental costs estimates depending on whether these esti-
mates are based on resource use of bundled unit Z or its detailed
elements (i.e., X and Y). RESULTS: The bundling strategy will
produce a different estimate of relative incremental costs
between treatment groups if the proportions of each element of
the bundled resource item are not equivalent between treatment
groups. Absolute incremental costs will differ if the mix of
resources in the sample is different than the mix of resources in
the population from which the price is estimated. CONCLU-
SIONS: Bundling to reduce the burden of very detailed resource
use data and price weights is justiﬁed if the resources are bundled
into resource units that are not composed of items that are used
more intensely in one treatment group. Price adjustments should
be considered if the relative resource intensity is different
between the price population and the trial population.
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OBJECTIVES: Researchers routinely estimate the ratio of the
cost to the effect (C/E) for the comparison of cost-effectiveness
among treatment groups. There are, however, several limitations
in applying C/E ratios in practice, including conceptual and sta-
tistical difﬁculties of ratio variables as well as issues concerning
the control of confounding biases. Treatment and comparison
groups, in observational study, are rarely comparable. Propen-
sity score methods (PSMs) as well as regression methods may be
applied to overcome confounding bias. To our knowledge, no
published study has compared the use of PSM to regression
methods for the evaluation of cost-effectiveness. The objective of
this study, therefore, is to report on the C/E ratio test, the PSM,
and a regression-based statistical model. METHODS: Simulated
data were used to compare results derived from the C/E ratio
test, the PSM, and a regression-based statistical model.
RESULTS: Results from the statistical and PSM models revealed
that cost-effectiveness evaluations can be confounded by
patients’ characteristics. CONCLUSIONS: Compared with the
crude estimate, PSM and regression-based methods can be 
used with observational data to estimate treatment group cost-
effectiveness differences controlling for observed heterogeneity.
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HAZARD MODELS INTO COST-EFFECTIVENESS
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Gold KF
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OBJECTIVES: Until now, the input to CE simulations was pri-
marily the probability of events and costs associated with them.
The probabilities are based on raw frequency data available or
logistic regression models. The goal of this research improve sim-
ulations by incorporating Cox proportional hazards (CPH)
analyses into these models to increase their validity and useful-
ness to policy makers. METHODS: A CPH analysis estimates
the coefﬁcients of a linear combination of predictors. Raising this
to the “e” power provides the hazard ratio comparing a group
of subjects deﬁned by a speciﬁc vector of predictors to an
“average” referent group. Once a Cox model is estimated, we
deﬁne a hazard ISOBAR as the set of values that make the linear
combination of predictors equal to a constant “c”. “C” can be
varied freely. This “c” can be used as the criteria for interven-
303Abstracts
tion assignment. The higher the “c” the smaller the sample to
receive intervention but it is expected that the cost-effectiveness
ratio would be higher. RESULTS: A simulated data set repre-
senting a 10-year study is generated with three predictors includ-
ing a risk factor “R” as well as an outcome “D” and time to
event. A logistic regression model was estimated to predict prob-
abilities used as inputs to a ﬁxed cost per event Markov model.
Selection of sample to receive intervention used hazard ISOBARS
as cutpoints and is compared to selection based on simple risk
factor cut points. ISOBARS for c = 0, 1, . . . 4 were used. It is
useful to note that when c = 0, “e” to the c equals one and splits
the sample into those above average risk and those below
average risk. Intervention assignment based on risk alone used
break points of top 50th, 25th and 10th percentile. CONCLU-
SIONS: Hazard ISOBAR cutpoints for interventions yielded
larger cost-effectiveness ratios than those generated by risk cut-
points alone.
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OBJECTIVE: Clinical trials conducted in multiple countries face
a major analytical hurdle in terms of accounting for costs. The
problem stems from the difference in currency units. Studies that
attempt to analyze these trial results either report the cost-
effectiveness ratios and incremental cost-effectiveness ratios for
each country separately, or opt to use one major currency as a
common denominator. This study offers to measure an incre-
mental cost-effectiveness elasticity (ICEE) as a methodological
approach for aggregation of costs and outcomes information
from Multicenter studies. METHODS: In economics, the notion
of elasticity is used to measure responsiveness of an endogenous
variable with respect to the change in an exogenous variable.
This responsiveness can be calculated using the notion of slope.
However, unlike the slope, which takes into account the unit of
measurement, the elasticity, which measures percentage change
in the endogenous variable per percentage change in the exoge-
nous variables, is unit-free. In analyzing Multicenter clinical trial
data, the measurement of incremental cost-effectiveness ratios
faces similar challenges and results are not comparable across
countries. To get around this measurement problem, the notion
of ICEE is used in this study. RESULTS: Using data published
from Advair cost-effectiveness studies, it is shown that control-
ling for inﬂation, an incremental expenditure of 1% on Advair,
yields an increase in episode-free-days and symptom-free-days by
12.42 % and 9.77%, respectively, compared with competitor
drugs. There was no loss of generality in the interpretation of
the responsiveness of the effects with respect to the costs. CON-
CLUSIONS: ICEE calculated across multiple centers show 
that the results are comparable with the incremental cost-
effectiveness ratios. This methodology could allow comparison
of cost-effectiveness studies across centers without resorting to
currency conversion. This methodology should therefore be used
in lieu of the incremental cost-effectiveness ratios.
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OBJECTIVES: This paper provides a systematic treatment of the
correction for nonrandom sample selection bias of medical cost
data where the selection rule is described by a censored regres-
sion model. METHODS: The proposed method ﬁrst uses the
duration of time a patient is tracked for the selection, rather than
a binary variable, namely whether or not the duration is cen-
sored. Second, using Tobit residuals instead of the inverse Mills
Ratio allows us to decrease large variances introduced by the
Heckman model when there a no exclusion restrictions.
RESULTS: We show that the resulting estimators are consistent
and asymptotically normal. Simulation studies conﬁrmed our
results. Moreover, we derive a simple test to determine possible
sample selection bias due to censoring. Data from a study on the
medical cost of cancer is used as an application of the method.
CONCLUSIONS: We applied OLS, Heckit, Lin[2000],
Lin[2003] methods as well as our proposed method to see how
they would differ in practice. Lin’s methods and the proposed
method were most efﬁcient relative to other methods. In addi-
tion, an advantage of our method was a test of whether selec-
tion bias exists in our data set.
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OBJECTIVES: The objective of this paper is to explain and illus-
trate the usefulness and limitations of bootstrapping method-
ologies and to improve applied health economics research 
by encouraging researchers to rely on rigorous empirical tests
when selecting the most appropriate bootstrapping method.
METHODS: Pair, parametric, nonparametric, and wild boot-
strapping types are analyzed for linear, non linear, instrumental
variable (IV) and discrete choice models. For each model, guide-
lines for selecting a consistent and efﬁcient bootstrapping
method are provided, and percentage deviations from the other
methods are calculated. The Medstat MarketScan® Research
Databases for 1995–2000 were used in this study. Patients with
evidence of asthma were selected from claims, encounter, enroll-
ment, and pharmaceutical data ﬁles. Separate models were esti-
mated for patients in fee-for-service (FFS) and non-FFS plans
based on likelihood tests. Total cost was estimated using linear,
non linear, and IV approaches. The ratio of controller to reliever
medication was used as an IV. Hospitalization was estimated
using a discrete-choice model. Control variables included demo-
graphics, clinical, and county characteristics. RESULTS: We
found that the selection of an inappropriate bootstrapping
methodology can yield results that deviate greatly from the
results produced using the appropriate methodology. Increase in
bias in the estimation of standard errors affects the signiﬁcance
of the coefﬁcients. CONCLUSIONS: There is no single boot-
strapping method that can be applied in all situations since 
the behavior of the bootstrap depends critically on both the 
statistic being examined and approximation to the underlying
population distribution function. In our example, the greatest
deviance was attained between parametric residual bootstrap-
ping and consistent and efﬁcient wild bootstrapping when errors
are heteroskedastic and not normal for estimation of non-linear
model.
